A prospective study of the effect by the biopsy in the rebamipide medication to the ulcer recovery after the endoscopic submucosal dissection (ESD) to a gastric tumor

A prospective study of the effect by the biopsy in the rebamipide medication to the ulcer recovery after the endoscopic submucosal dissection (ESD) to a gastric tumor - A prospective study of the effect by the biopsy in the rebamipide medication to the ulcer recovery after the endoscopic submucosal dissection (ESD) to a gastric tumor

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010188

Enrollment

Registered

2013-03-07

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric tumor lesion

Interventions

evaluations of treatments one week after to the artificial ulcer by endoscopycal treatment,lansoprazole independent medical treatment group evaluations of treatments one week after to the artificial

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who is planning enforcement of an endoscopic submucosal dissection (ESD)

Exclusion criteria

Exclusion criteria: The patient who has taken the antiplatelet agent and the anticoagulant. The steroid internal use patient to whom ulcer healings rates differs from usual, glycemic control bad diabetics.

Design outcomes

Primary

Measure	Time frame
Evaluation of the existence of the promotion of ulcer recovery according to rebamipide additional medication to after endoscopycaltreatment artificial ulcer.	—

Secondary

Measure	Time frame
Effects by proton ponp inhibitor single dose	—

Countries

Japan

Contacts

Public Contactkenshi matsumoto

juntendo university gastroenterology

kmatumo@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026